Importantly, AKT inhibition sensitized to SM83/CPT treatment also CRC cell lines bearing wild type PI3K (Figure S4), further supporting the idea that AKT counteracts the pro-death stimulus deriving from oncogenic KRAS. This evidence concerns the gene KRAS and colorectal carcinoma.